Clinical Data FibroGen announced data from its Phase 2 study through the European Respiratory Journal on FG-3019 monoclonal antibody on treatment of idiopathic pulmonary fibrosis (IPF).  The study was designed to measure safety and efficacy and found that a "majority of subjects in the study (65%) exhibited an increase in fibrosis, 35% exhibited stable or improved fibrosis at week 48" and "27.0% experienced a total of 38 treatment-emergent serious adverse events (SAEs) during the trial."  FibroGen is encouraged by the data and is conducting a Phase 2 placebo controlled study.